Randomised clinical trial: Lactobacillus GG modulates gut microbiome, metabolome and endotoxemia in patients with cirrhosis

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Alimentary Pharmacology and Therapeutics

• Publication date

  2014-05-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1111/apt.12695PMID 24628464PMCID PMC3989370
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Altered profile of human gut microbiome is associated with cirrhosis and its complications.

  2014cited by this paper
• A Randomized, Double-Blind, Controlled Trial Comparing Rifaximin Plus Lactulose With Lactulose Alone in Treatment of Overt Hepatic Encephalopathy

  2013cited by this paper
• The nutritional management of hepatic encephalopathy in patients with cirrhosis: International society for hepatic encephalopathy and nitrogen metabolism consensus

  2013cited by this paper
• Pathological bacterial translocation in cirrhosis: pathophysiology, diagnosis and clinical implications

  2013cited by this paper
• The gut microbiota and the liver. Pathophysiological and clinical implications.

  2013cited by this paper
• Meta‐analysis: Lactobacillus GG for treating acute gastroenteritis in children – updated analysis of randomised controlled trials

  2013cited by this paper
• Comparative Genomic and Functional Analysis of 100 Lactobacillus rhamnosus Strains and Their Comparison with Strain GG

  2013cited by this paper
• Modulation of the fecal bile acid profile by gut microbiota in cirrhosis.

  2013influential reference
• Modulation of the Metabiome by Rifaximin in Patients with Cirrhosis and Minimal Hepatic Encephalopathy

  2013cited by this paper
• Colonic mucosal microbiome differs from stool microbiome in cirrhosis and hepatic encephalopathy and is linked to cognition and inflammation.

  2012cited by this paper
• Cognitive performance as a predictor of hepatic encephalopathy in pretransplant patients with cirrhosis receiving psychoactive medications: A prospective study

  2012cited by this paper
• Characterization of a probiotic-derived soluble protein which reveals a mechanism of preventive and treatment effects of probiotics on intestinal inflammatory diseases

  2012cited by this paper
• Linkage of gut microbiome with cognition in hepatic encephalopathy.

  2012influential reference
• Safety and Tolerability of Lactobacillus reuteri DSM 17938 and Effects on Biomarkers in Healthy Adults: Results from a Randomized Masked Trial

  2012cited by this paper
• Immune dysfunction and infections in patients with cirrhosis.

  2011cited by this paper
• Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease

  2011cited by this paper
• Characterization of fecal microbial communities in patients with liver cirrhosis

  2011cited by this paper
• Probiotics for patients with hepatic encephalopathy.

  2011cited by this paper
• Diversity of the autochthonous colonic microbiota

  2011cited by this paper
• Extending Biochemical Databases by Metabolomic Surveys*

  2011cited by this paper
• Quantitative Assessment of the Human Gut Microbiome Using Multitag Pyrosequencing

  2010cited by this paper
• Network‐Based Modeling of the Human Gut Microbiome

  2010cited by this paper
• Review article: the modern management of hepatic encephalopathy

  2010cited by this paper
• Quantitative strain‐specific detection of Lactobacillus rhamnosus GG in human faecal samples by real‐time PCR

  2009influential reference
• Statistical Methods for Detecting Differentially Abundant Features in Clinical Metagenomic Samples

  2009cited by this paper
• Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial.

  2008cited by this paper
• Executive summary: scientific and regulatory challenges of development of probiotics as foods and drugs.

  2008cited by this paper
• Inhibitory control test for the diagnosis of minimal hepatic encephalopathy.

  2008cited by this paper
• Probiotic Prophylaxis in Predicted Severe Acute Pancreatitis: A Randomised, Double-Blind, Placebo-Controlled Trial.

  2008cited by this paper
• Probiotic Yogurt for the Treatment of Minimal Hepatic Encephalopathy

  2008cited by this paper
• Role of ammonia and inflammation in minimal hepatic encephalopathy

  2007cited by this paper
• Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis

  2006cited by this paper
• Functional Analysis of luxS in the Probiotic Strain Lactobacillus rhamnosus GG Reveals a Central Metabolic Role Important for Growth and Biofilm Formation

  2006cited by this paper
• Chronic low intake of protein or vitamins increases the intestinal epithelial cell apoptosis in Wistar/NIN rats.

  2005cited by this paper
• Minimal hepatic encephalopathy: diagnosis, clinical significance and recommendations.

  2005cited by this paper
• [The protective effect of supplementation of probiotics combined with riboflavin on the intestinal barrier of the rats after scald injury].

  2004cited by this paper
• Cytoscape: a software environment for integrated models of biomolecular interaction networks.

  2003cited by this paper
• Hepatic encephalopathy—Definition, nomenclature, diagnosis, and quantification: Final report of the Working Party at the 11th World Congresses of Gastroenterology, Vienna, 1998

  2002cited by this paper
• PLS-regression: a basic tool of chemometrics

  2001cited by this paper
• A microbiology investigation on probiotic pharmaceutical products used for human health.

  1997cited by this paper
• Detection and possible origins of aminomalonic acid in protein hydrolysates.

  1992cited by this paper
• Antimicrobial substance from a human Lactobacillus strain

  1987cited by this paper
• The Sickness Impact Profile: Development and Final Revision of a Health Status Measure

  1981cited by this paper

• ACG Clinical Guideline: Hepatic Encephalopathy.

  2026cites this paper
• Lacticaseibacillus rhamnosus B6 alleviates metabolic dysfunction-associated fatty liver disease by suppressing intestinal LPS synthesis and regulating lipid metabolism.

  2026cites this paper
• A multi-strain probiotic modulates gut microbiome composition, intestinal barrier integrity and inflammation in a multi-compartmental in vitro gut model of decompensated alcohol-related advanced chronic liver disease.

  2026cites this paper
• Clinical Evidence on the Health Benefits and Safety of Probiotic Lacticaseibacillus rhamnosus: A Systematic Review.

  2025cites this paper
• Interaction Between Human Microbiota, Immune System, and Hepatitis C Virus Infection: A Narrative Review

  2025cites this paper
• Progress and prospects of gut microbiota-targeted therapy for primary biliary cholangitis

  2025cites this paper
• Characteristics and Clinical Significance of Gut Microbiota in Patients With Epstein‐Barr Virus‐Associated Liver Dysfunction

  2025cites this paper
• Protective Effects of Bifidobacterium Breve MCC1274 as a Novel Therapy for Alzheimer’s Disease

  2025cites this paper
• Probiotics for the Management of Liver Cirrhosis and Its Complications.

  2025cites this paper
• Intestinal Microbes, Metabolites, and Hormones in Alcohol-Associated Liver Disease

  2025cites this paper
• Gut Microbiota and the Gut–Liver Axis in Liver Disease: From Chronic Viral Hepatitis to Cirrhosis, Hepatocellular Carcinoma, and Microbiome-Based Therapies

  2025cites this paper
• The effects of Lacticaseibacillus rhamnosus GG supplementation on gastrointestinal and respiratory outcomes: a systematic review and meta-analysis of randomized controlled trials.

  2025cites this paper
• The role of gut microbiota in modulating immune responses in chronic liver disease: a systematic review and meta-analysis

  2025cites this paper
• Effects of probiotics on cognitive function across the human lifespan: a meta-analysis

  2025cites this paper
• Letter: Methodological Caveats in Zhang et al.-Gut Microbiota and Metabolism in Cirrhotic Portal Hypertension.

  2025cites this paper
• Management of hepatic encephalopathy following transjugular intrahepatic portosystemic shunts: Current strategies and future directions

  2025cites this paper
• Probiotics—A Promising Novel Therapeutic Approach in the Management of Chronic Liver Diseases

  2024cites this paper
• Research reviews and prospects of gut microbiota in liver cirrhosis: a bibliometric analysis (2001–2023)

  2024cites this paper
• Microbiome bacterial influencers of host immunity and response to immunotherapy

  2024cites this paper
• Efficacy and Safety of Variable Treatment Options in the Prevention of Hepatic Encephalopathy: A Systematic Review and Network Meta-Analysis

  2024cites this paper
• Social Impact of Hepatic Encephalopathy.

  2024cites this paper
• Microbiota and Gut–Liver Axis: An Unbreakable Bond?

  2024cites this paper
• Present and future of fecal microbiome transplantation in cirrhosis.

  2024cites this paper
• Efficacy of Probiotics on Improvement of Health Outcomes in Cirrhotic Liver Disease Patients: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.

  2024influential citation
• Gut microbes combined with metabolomics reveal the protective effects of Qijia Rougan decoction against CCl4-induced hepatic fibrosis

  2024cites this paper
• Probiotics are beneficial for liver cirrhosis: a systematic review and meta-analysis of randomized control trials

  2024cites this paper
• Gut Bacteria in Alcohol-Associated Liver Disease.

  2024cites this paper
• Chronic Liver Disease and Promising Therapeutic Strategy: A Concise Review

  2024cites this paper
• Viral Liver Disease and Intestinal Gut–Liver Axis

  2024cites this paper
• From Cirrhosis to the Dysbiosis (A Loop of Cure or Complications?)

  2024cites this paper
• Gut‑liver axis in liver disease: From basic science to clinical treatment (Review)

  2024cites this paper
• Therapeutic possibilities of gut microbiota modulation in acute decompensation of liver cirrhosis

  2023cites this paper
• Role of gut microbiota in the pathogenesis and therapeutics of minimal hepatic encephalopathy via the gut-liver-brain axis

  2023cites this paper
• Gut Microbiota and Neuroinflammation in Acute Liver Failure and Chronic Liver Disease

  2023cites this paper
• Do gut microbiome‐targeted therapies improve liver function in cirrhotic patients? A systematic review and meta‐analysis

  2023influential citation
• Impact of probiotics on cognition and constipation in the elderly: A meta-analysis

  2023cites this paper
• Efficacy of probiotics in the treatment of minimal hepatic encephalopathy: A systematic review and meta-analysis

  2023influential citation
• The Role of the Gastrointestinal Microbiome in Liver Disease

  2023cites this paper
• Investigation of therapeutic effects of rhubarb decoction retention enema on minimal hepatic encephalopathy in rats based on 16S rDNA gene sequencing and bile acid metabolomics.

  2023cites this paper
• The causality between gut microbiome and liver cirrhosis: a bi-directional two-sample Mendelian randomization analysis

  2023cites this paper
• Hepatoprotective effects of natural drugs: Current trends, scope, relevance and future perspectives.

  2023cites this paper
• Probiotic management and inflammatory factors as a novel treatment in cirrhosis: A systematic review and meta-analysis

  2023cites this paper
• A Comprehensive Overview of the Past, Current, and Future Randomized Controlled Trials in Hepatic Encephalopathy

  2023cites this paper
• A meta-analysis of microbiome therapies for hepatic encephalopathy

  2023cites this paper
• Roles of human gut microbiota in liver cirrhosis risk: a two-sample mendelian randomization study.

  2023cites this paper
• Evaluation and Management of Nutritional Consequences of Chronic Liver Diseases

  2023cites this paper
• Sarcopenia in cirrhosis: Prospects for therapy targeted to gut microbiota

  2023cites this paper
• Alcohol Use Disorder and the Gut Microbiome

  2023cites this paper
• Comparison of the effects of probiotics, rifaximin, and lactulose in the treatment of minimal hepatic encephalopathy and gut microbiota

  2023cites this paper
• Gut microbiome-brain-cirrhosis axis.

  2023cites this paper
• Impact of a Single Dose of a Probiotic Nutritional Supplement (AB001) on Absorption of Ethylalcohol: Results From a Randomized Double-Blind Crossover Study

  2023cites this paper
• Intestinal dysbiosis and probiotic use: its place in hepatic encephalopathy in cirrhosis

  2023cites this paper
• The Intestinal Microbiota in the Development of Chronic Liver Disease: Current Status

  2023cites this paper
• Gut Lactobacillus and Probiotics Lactobacillus lactis/rhamnosis Ameliorate Liver Fibrosis in Prevention and Treatment

  2023cites this paper
• Update in the treatment of the complications of cirrhosis.

  2023cites this paper
• Gut Microbiome and Organ Fibrosis

  2022cites this paper
• Alterations of gut microbiome and effects of probiotic therapy in patients with liver cirrhosis: A systematic review and meta-analysis

  2022cites this paper
• Minimal Hepatic Encephalopathy Affects Daily Life of Cirrhotic Patients: A Viewpoint on Clinical Consequences and Therapeutic Opportunities

  2022cites this paper
• Characteristics and Clinical Significance of Intestinal Microbiota in Patients with Chronic Hepatitis B Cirrhosis and Type 2 Diabetes Mellitus

  2022cites this paper
• The Link between Gut Microbiota and Hepatic Encephalopathy

  2022cites this paper
• Cancer-Associated Microbiota: From Mechanisms of Disease Causation to Microbiota-Centric Anti-Cancer Approaches

  2022cites this paper
• Trust Your Gut: The Association of Gut Microbiota and Liver Disease

  2022cites this paper
• Gut microbiota dysbiosis: The potential mechanisms by which alcohol disrupts gut and brain functions

  2022cites this paper
• The gut microbiota - a vehicle for the prevention and treatment of hepatocellular carcinoma.

  2022cites this paper
• Probiotics Exhibit Strain-Specific Protective Effects in T84 Cells Challenged With Clostridioides difficile-Infected Fecal Water

  2022cites this paper
• The Lactobacillus as a Probiotic: Focusing on Liver Diseases

  2022influential citation
• High-throughput technologies in probiotics science

  2022cites this paper
• Des probiotiques pour l’encéphalopathie hépatique

  2022cites this paper
• B. infantis EVC001 Is Well-Tolerated and Improves Human Milk Oligosaccharide Utilization in Preterm Infants in the Neonatal Intensive Care Unit

  2022cites this paper
• Empyema and bacteremia caused by Aeromonas hydrophila: Case report and review of the literature.

  2022cites this paper
• Ameliorative effect of Lactobacillus rhamnosus GG on acetaminophen-induced hepatotoxicity via PKC/Nrf2/PGC-1α pathway

  2022cites this paper
• Gut microbiota modulation in acute decompensation of liver cirrhosis: theory and therapeutic potential

  2022cites this paper
• Intestinal virome in patients with alcohol use disorder and after abstinence

  2022cites this paper
• Probiotics in hepatology: An update

  2021cites this paper
• The Potential of Probiotics to Eradicate Gut Carriage of Pathogenic or Antimicrobial-Resistant Enterobacterales

  2021cites this paper
• Microbiota shaping — the effects of probiotics, prebiotics, and fecal microbiota transplant on cognitive functions: A systematic review

  2021cites this paper
• Eicosapentaenoic and docosahexaenoic acids attenuate hyperglycemia through the microbiome-gut-organs axis in db/db mice

  2021cites this paper
• Therapeutic Applications of Resveratrol in Hepatic Encephalopathy through Its Regulation of the Microbiota, Brain Edema, and Inflammation

  2021cites this paper
• Diet-Regulating Microbiota and Host Immune System in Liver Disease

  2021cites this paper
• The gut microbiota in hepatic encephalopathy

  2021cites this paper
• The effect of probiotics on cognitive function across the human lifespan: A systematic review.

  2021cites this paper
• Butyrate administration strengthens the intestinal epithelium and improves intestinal dysbiosis in a cholestasis fibrosis model

  2021cites this paper
• Use of Probiotics as a Prophylaxis for Hepatic Encephalopathy: A Review Article

  2021cites this paper
• Microbiome Therapeutics for Hepatic Encephalopathy.

  2021cites this paper
• Probiotic Lactobacillus rhamnosus GG (LGG) restores intestinal dysbacteriosis to alleviate upregulated inflammatory cytokines triggered by femoral diaphyseal fracture in adolescent rodent model.

  2021cites this paper
• The intestinal microbiota as a therapeutic target in the treatment of NAFLD and ALD.

  2021cites this paper
• Genetically engineered E. coli Nissle attenuates hyperammonemia and prevents memory impairment in bile‐duct ligated rats

  2021cites this paper
• Current approach to treatment of minimal hepatic encephalopathy in patients with liver cirrhosis

  2021cites this paper
• Translocation of gut microbiota in liver cirrhosis: mechanisms, clinical significance, and markers

  2021cites this paper
• Gut microbiome changes in Nonalcoholic fatty liver disease & alcoholic liver disease.

  2021cites this paper
• Role of Microbiota-Derived Metabolites in Alcoholic and Non-Alcoholic Fatty Liver Diseases

  2021cites this paper
• Microbial Therapeutics in Liver Disease

  2021cites this paper
• Gut Microbes and Hepatic Encephalopathy: From the Old Concepts to New Perspectives

  2021cites this paper
• Influence of Probiotics Administration Before Liver Resection in Patients with Liver Disease: A Randomized Controlled Trial

  2021cites this paper
• Gut Microbiome-Mediated Alteration of Immunity, Inflammation, and Metabolism Involved in the Regulation of Non-alcoholic Fatty Liver Disease

  2021cites this paper
• Mechanisms of Gut Microbiota Modulation by Food, Probiotics, Prebiotics and More

  2021cites this paper
• Probiotics improve the neurometabolic profile of rats with chronic cholestatic liver disease

  2021cites this paper
• Significance of gut microbiota in alcoholic and non-alcoholic fatty liver diseases

  2021cites this paper
• Therapeutic potential of Saccharomyces boulardii in liver diseases: from passive bystander to protective performer?

  2021cites this paper
• Eicosapentaenoic and Docosahexaenoic acids Differentially Alter Gut Microbiome and Reverse High-Fat Diet-Induced Insulin Resistance.

  2020cites this paper